Table 2 Strategic placement of charged residues in the C-terminal tail can enhance cellular activity and mitigate off-target effects

From: Design-rules for stapled peptides with in vivo activity and their application to Mdm2/X antagonists

Peptide

C-terminus (1st position is residue 14)

Binding

Solubility

Cell EC50 (4 hr, 0% FBS) (µM)

Cell EC50 (16 hr, 10% FBS) (µM)

Proliferation EC50

Proliferation EC50

Proliferation % inhibition at 50 µM

KD (nM)

(µM)

  

HCT116

Ca Ski

Ca Ski

    

(On-target) (µM)

(Off-target) (µM)

%

MP-081

-SA2-NH2

5.0

105

0.49

0.86

2.3

32.8

85.5

MP-688*

-A6-NH2

21.5

N.D.

0.16

1.3

12.0

45.1

53.4

ALRN-6924*

-A5-dA-NH2

2.46

P.B.

0.14

0.32

0.87

47.5

48.7

MP-032

-A6-NH2

9.45

P.B.

0.14

0.24

0.96

26.6

47.5

MP-464

-A5-dA-NH2

30.9

157

0.43

0.29

0.42

>49.75

9.9

MP-8834

-EA4-dA-NH2

1.1

167

1.0

3.4

1.4

>49.75

-3.2

MP-965

-AEA3-dA-NH2

5.7

161

1.1

2.2

2.7

>49.75

16.2

MP-833

-A2EA2-dA-NH2

3.1

154

0.96

0.19

0.14

>49.75

-11.1

MP-835

-A3EA-dA-NH2

<1

162

0.65

0.82

0.55

>49.75

-10.3

MP-837

-A4E-dA-NH2

5.7

160

0.76

1.67

0.66

>49.75

8.6

MP-836

-A5E-NH2

<1

164

0.55

1.06

1.05

>49.75

13.2

MP-897

-(Gla)A4-dA-NH2

<1

163

0.79

0.52

0.79

>49.75

-19.1

MP-060

-A5F-NH2

2.1

P.B.

0.17

2.7

0.46

>49.75

18.6

MP-228

-A2FA2-dA-NH2

4.2

2

0.21

0.69

2.7

30.7

68.7

MP-040

-(A2F)2-NH2

27.1

P.B.

0.036

0.75

1.22

>49.75

4.4

MP-063

-A2FA2-dF-NH2

56.0

9

0.11

2.13

2.78

>49.75

24.0

MP-288

-A2FA2-(aMe-F)-NH2

23.7

12

0.10

2.68

2.74

>49.75

5.3

MP-229

-A2FA-(aMe-E)-F-NH2

4.8

153

0.20

0.21

2.32

19.9

102.7

MP-802

-((hS)2F)2-NH2 (early isomer)

7.4

P.B.

0.23

0.75

4.58

19.1

95.2

MP-803

-((hS)2F)2-NH2 (late isomer)

121.3

1

0.45

2.49

2.03

27.0

84.5

  1. Constant N-terminal sequence of Ac-K(N3)-βA-LTF(R8)EYWAQ(Cba)(S5)-, except for peptides marked with a asterisk which instead have an N-terminal sequence of Ac-LTF(R8)EYWAQL(S5)-. N.D.: Data not collected, P.B.: Poorly behaved; result inconclusive. Compounds were tested in duplicate.